I'm going to speak about the orphan drug environment because that's where I've worked the most. We had a study done out of Ottawa that actually looked at orphan drug or rare disease drug decision-making internationally. What's interesting is that lots of countries have processes, but we haven't been able to.... They have at least frameworks in place to support decision-making, much as we have in British Columbia—
On December 6th, 2016. See this statement in context.